Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Sees Large Increase in Short Interest

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the target of a significant increase in short interest in February. As of February 13th, there was short interest totaling 181,710 shares, an increase of 26.1% from the January 29th total of 144,124 shares. Currently, 1.3% of the company’s stock are short sold. Based on an average daily volume of 91,000 shares, the days-to-cover ratio is presently 2.0 days. Based on an average daily volume of 91,000 shares, the days-to-cover ratio is presently 2.0 days. Currently, 1.3% of the company’s stock are short sold.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KAPA. FNY Investment Advisers LLC purchased a new stake in shares of Kairos Pharma during the third quarter valued at approximately $27,000. XTX Topco Ltd lifted its position in Kairos Pharma by 290.8% in the 4th quarter. XTX Topco Ltd now owns 48,494 shares of the company’s stock valued at $34,000 after acquiring an additional 36,086 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new stake in Kairos Pharma during the 3rd quarter valued at $54,000.

Analyst Ratings Changes

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Kairos Pharma in a research report on Wednesday, November 19th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $8.33.

Kairos Pharma Trading Up 0.9%

NYSEAMERICAN KAPA opened at $0.63 on Thursday. Kairos Pharma has a 12 month low of $0.40 and a 12 month high of $2.11. The stock’s fifty day moving average price is $0.70 and its 200-day moving average price is $0.96. The stock has a market cap of $13.11 million, a P/E ratio of -2.03 and a beta of 2.28.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.